Prima BioMed (IMMP) Competitors $1.95 +0.09 (+4.84%) Closing price 04:00 PM EasternExtended Trading$1.93 -0.02 (-1.03%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMMP vs. SYRE, PRAX, UPB, VALN, CRMD, TNGX, URGN, IMNM, ABUS, and IMTXShould you be buying Prima BioMed stock or one of its competitors? The main competitors of Prima BioMed include Spyre Therapeutics (SYRE), Praxis Precision Medicines (PRAX), Upstream Bio (UPB), Valneva (VALN), CorMedix (CRMD), Tango Therapeutics (TNGX), Urogen Pharma (URGN), Immunome (IMNM), Arbutus Biopharma (ABUS), and Immatics (IMTX). These companies are all part of the "pharmaceutical products" industry. Prima BioMed vs. Its Competitors Spyre Therapeutics Praxis Precision Medicines Upstream Bio Valneva CorMedix Tango Therapeutics Urogen Pharma Immunome Arbutus Biopharma Immatics Prima BioMed (NASDAQ:IMMP) and Spyre Therapeutics (NASDAQ:SYRE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations. Which has more volatility & risk, IMMP or SYRE? Prima BioMed has a beta of 1.87, indicating that its share price is 87% more volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 2.9, indicating that its share price is 190% more volatile than the S&P 500. Which has better valuation and earnings, IMMP or SYRE? Prima BioMed has higher revenue and earnings than Spyre Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrima BioMed$6.69M42.79-$39.78MN/AN/ASpyre Therapeutics$890K1,131.31-$208.02M-$3.40-4.90 Does the media favor IMMP or SYRE? In the previous week, Spyre Therapeutics had 5 more articles in the media than Prima BioMed. MarketBeat recorded 5 mentions for Spyre Therapeutics and 0 mentions for Prima BioMed. Spyre Therapeutics' average media sentiment score of 0.62 beat Prima BioMed's score of 0.00 indicating that Spyre Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Prima BioMed Neutral Spyre Therapeutics Positive Do analysts recommend IMMP or SYRE? Prima BioMed presently has a consensus target price of $7.00, suggesting a potential upside of 258.97%. Spyre Therapeutics has a consensus target price of $54.29, suggesting a potential upside of 225.65%. Given Prima BioMed's higher probable upside, analysts plainly believe Prima BioMed is more favorable than Spyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prima BioMed 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Spyre Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.00 Do institutionals and insiders hold more shares of IMMP or SYRE? 2.3% of Prima BioMed shares are held by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are held by institutional investors. 3.1% of Prima BioMed shares are held by company insiders. Comparatively, 6.2% of Spyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is IMMP or SYRE more profitable? Prima BioMed's return on equity of 0.00% beat Spyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Prima BioMedN/A N/A N/A Spyre Therapeutics N/A -71.30%-38.69% SummarySpyre Therapeutics beats Prima BioMed on 9 of the 14 factors compared between the two stocks. Get Prima BioMed News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMMP vs. The Competition Export to ExcelMetricPrima BioMedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$286.24M$3.35B$6.10B$10.62BDividend YieldN/A2.28%5.64%4.69%P/E RatioN/A22.1685.6627.13Price / Sales42.79265.75527.82206.05Price / CashN/A46.3226.3031.10Price / Book3.109.9612.926.67Net Income-$39.78M-$52.42M$3.30B$276.23M7 Day Performance8.94%5.95%4.80%3.31%1 Month Performance18.18%11.59%8.11%10.76%1 Year Performance-4.88%25.01%75.85%33.58% Prima BioMed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMPPrima BioMed1.0509 of 5 stars$1.95+4.8%$7.00+259.0%-9.3%$273.02M$6.69M0.002,021SYRESpyre Therapeutics2.9791 of 5 stars$15.29+2.8%$56.17+267.3%-45.5%$898.77M$890K-4.5073News CoverageAnalyst DowngradePRAXPraxis Precision Medicines2.2671 of 5 stars$48.33+14.5%$85.56+77.0%-16.3%$888.71M$8.55M-3.93110UPBUpstream Bio1.9454 of 5 stars$16.65+1.6%$56.50+239.3%N/A$883.04M$2.37M0.0038VALNValneva2.514 of 5 stars$10.15-0.3%$15.00+47.8%+96.0%$874.74M$183.52M-10.36700Gap UpCRMDCorMedix3.1151 of 5 stars$11.27+0.6%$18.00+59.7%+27.4%$874.26M$43.47M15.0330Analyst DowngradeTNGXTango Therapeutics2.3703 of 5 stars$7.45-2.0%$10.50+40.9%+11.2%$845.58M$42.07M-5.6090URGNUrogen Pharma3.9571 of 5 stars$17.99+0.2%$32.00+77.9%+37.0%$830.44M$90.40M-5.42200Analyst ForecastIMNMImmunome1.4508 of 5 stars$9.77+4.0%$23.20+137.5%-6.0%$817.35M$9.04M-3.1740ABUSArbutus Biopharma1.3168 of 5 stars$4.43+4.2%$5.00+12.9%+14.1%$814.72M$6.17M-15.2890Negative NewsIMTXImmatics2.8184 of 5 stars$6.85+2.2%$15.00+119.0%-13.4%$814.39M$168.65M-10.54260Positive News Related Companies and Tools Related Companies Spyre Therapeutics Alternatives Praxis Precision Medicines Alternatives Upstream Bio Alternatives Valneva Alternatives CorMedix Alternatives Tango Therapeutics Alternatives Urogen Pharma Alternatives Immunome Alternatives Arbutus Biopharma Alternatives Immatics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMMP) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIs This Warren’s Buffett’s #1 AI Investment?Did you know that Warren Buffett is investing in what Jeff Brown believes will be the next generation of artif...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredWarren Buffett’s #1 AI Stock is Not Even on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A Millionaire With SEVEN Clicks? $1,000 in just seven stocks in 2004 could have turned into a million-dolla...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prima BioMed Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Prima BioMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
